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Thrombotic Thrombocytopenic Purpura Revisited: 
Upshaw Schulman Syndrome in a 20-Year-Old Male
Judy Wang, MD and Niluk Peiris, MD 
Case Report
A 20-year-old male with no significant past medical history 
presented to an outside hospital with a two-week history of 
progressive fatigue, malaise and decreased appetite. Prior to 
these events, he had been in his usual state of health with normal 
exercise tolerance and energy level. Upon development of his 
symptoms, the patient felt as though he had developed an upper 
respiratory infection (URI). The URI symptoms eventually 
resolved; however complaints of fatigue and malaise still 
remained. He then developed progressive dyspnea on exertion 
and tea-colored urine. The patient reported a singular febrile 
episode to 38.9˚C associated with nonbilious vomiting two days 
prior to admission. Upon further questioning, he admitted to 
a twenty-pound weight loss over the last month. The patient’s 
mother also noticed unprovoked bruising on his forearms 
bilaterally. He denied night sweats, gingival bleeding, epistaxis, 
hematuria, or melena.
The patient is of Afro-Jamaican descent; his family originating 
from Trinidad. He reported no family history of hematologic 
disorders, and only acknowledged a maternal grandmother 
with breast cancer. The patient denied chronic medications, 
including herbal and over-the-counter medications. He denied 
food or drug allergies, as well as alcohol, tobacco or illicit drug 
use. He reported being sexual active with one partner in the past 
6 months and denied any sexually transmitted infections.
Hospital Course
On admission to the outside hospital, laboratory results 
revealed a profound anemia (hemoglobin 6.3 g/dL) with an 
elevated red cell distribution width (RDW) (22.4%), thrombo-
cytopenia (platelet count 44 B/L) and acute kidney injury 
(serum creatinine 1.9 mg/dL). Subsequent testing reported 
the presence of 4+ schistocytes on peripheral blood smear 
concerning for microangiopathic hemolytic anemia (MAHA). 
Given his triad of anemia, thrombocytopenia and presence of 
schistocytes, there was a concern for thrombotic thrombocy-
topenic purpura (TTP). He was transferred to our institution 
for further management. Prior to transfer, the patient was 
medically supported with blood products and underwent a bone 
marrow biopsy that was determined to be non-malignant.
Upon arrival to our institution, further laboratory results 
revealed a significantly elevated lactate dehydrogenase (LDH) 
(956 IU/L) with essentially undetectable haptoglobin (<10 mg/
dL). Urinalysis was positive for 2+ protein and 1+ blood. Direct 
Coombs test was negative. Repeat peripheral blood smear was 
positive for the presence of 3+ schistocytes, confirming concern 
for TTP. The patient was transferred to the medical intensive 
care unit and immediately started on intravenous methylpred-
nisolone, folate, and blood products until an apheresis catheter 
could be placed for plasma exchange therapy. Once the catheter 
was placed, the patient underwent five sessions of plasma 
exchange therapy without complications. Human immuno-
deficiency virus (HIV) antibody, hepatitis B and C serologies 
were negative. His steroids were tapered, and blood counts and 
LDH were monitored daily. Upon discharge, hemoglobin had 
increased to 8.2 mg/dL, RDW 20.3%, platelet count 259 B/L, 
and LDH 263 IU/L. Haptoglobin had increased to 46 mg/dL and 
serum creatinine had improved to 0.8 mg/dL. A Disintegrin-like 
And Metalloprotease with ThromboSpondin type 1 member 
13 (ADAMTS13) activity was determined to be severely low 
at <5%, and ADAMTS13 inhibitor activity was <0.4 units. 
Following discharge, the patient returned to the Emergency 
Department two weeks later for fever of 38.4˚C and malaise, 
however blood counts showed hemoglobin 9.8 g/dL, RDW 
15.9%, platelet count 145 B/L, and serum creatinine 1.1 mg/dL, 
so he was deemed stable for close follow-up as an outpatient.
Introduction
Congenital thrombotic thrombocytopenic purpura (CTTP), 
also known as Upshaw-Schulman Syndrome (USS), is a very 
rare, but potentially life-threatening disease. It is characterized 
by the symptoms also seen in acquired or idiopathic TTP, 
including thrombocytopenia, MAHA, and subsequent 
microvascular thrombosis. However this constellation of 
symptoms is seen in conjunction with significant and persistent 
deficiency in ADAMTS13 with concurrent absence of an 
ADAMTS13 inhibitor. ADAMTS13 is a protease responsible for 
modifying the larger precursor of von Willebrand factor (vWF), 
a necessary component of the clotting cascade. Continued 
disruption of this process leads to microvascular embolization 
and may ultimately cause potential end organ failure, including 
heart, brain, and kidneys.
Historical Background
Cases concerning for CTTP were first reported in 1953, when 
Dacie and colleagues described a 6-year-old female who suffered 
repeated episodes of thrombocytopenia, hemolytic anemia, 
presence of schistocytes, and significant jaundice since birth. The 
young patient underwent splenectomy without improvement of 
symptoms, and eventually died of renal failure at age 7. Upon 
review of the patient’s family history, she had two other siblings, 
who were jaundiced as newborns and both died of hemorrhage 
by the age of 4. However the fourth child and both parents 
were asymptomatic, so Dacie suspected that the patient and her 
family had some yet to be determined inherited blood disorder.1 
In 1960, Schulman reported an 8-year-old female who suffered 
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from repeated bleeding episodes secondary to chronic thrombo-
cytopenia and MAHA. Symptoms dramatically improved with 
fresh frozen plasma (FFP), suggesting that the patient had a 
congenital deficiency in some “platelet-stimulating factor.”2 
Upshaw and colleagues in 1978 would later report a 29-year-old 
female who had repeated episodes of thrombocytopenia and 
MAHA since childhood, that was treated with FFP.3 
The syndrome for CTTP was coined by Rennard and Abe, 
who recognized the similarities between the Upshaw and 
Schulman’s cases, and they postulated that these patients 
developed their sequelae as a result of increased fibronectin 
during the symptomatic phase of their disease.4 However, 
multiple subsequent studies would later show there was no 
association with fibronectin and disease activity.5,6,7 The assay 
to assess ADAMTS13 activity was created in 1997, but it was 
not until 2001 that the link between ADAMTS13 mutation and 
subsequent deficiency and CTTP or USS was confirmed by Levy 
and colleagues by means of linkage analysis performed on four 
pedigrees with CTTP.8
Pathophysiology
USS is inherited through an autosomal recessive pattern, 
though based upon clinical evaluation of USS patients, there 
is a variable degree penetrance that does not necessarily follow 
a structured genotype-phenotype correlation.9 It is caused by 
mutations in the gene encoding ADAMTS13, and to date, there 
have been 76 distinct reported mutations.9 The majority of 
these mutations are compound heterozygous in patients (64% 
of reported USS cases), thereby making it difficult to connect 
specific gene mutations to presentation characteristics of clinical 
disease. However, it is noted that the majority of mutations 
occur in the N-terminus portion of the protein, a sequence that 
is responsible for encoding the domains specific to the metallo-
protease activity function of ADAMTS13.9
USS, just as idiopathic or acquired TTP (ATTP), occurs as a 
result of microthrombi formed from inappropriately formed 
vWF precursor complexes, causing embolic ischemic damage 
to end organs, typically heart, brain and kidney. Both are 
usually prompted by stress-inducing triggers, such as infection 
or pregnancy, but the etiology of microthrombi formation 
differs as do the prognosis and recurrence risk. In ATTP, 
microthrombi are formed as a result of auto-antibodies directed 
towards ADAMTS13, thereby acting as an inhibitor to the 
enzyme. In USS, an inherent deficiency in ADAMTS13 prevents 
appropriate modification of the vWF precursor, allowing 
formation of microthrombi.
VWF is a large glycoprotein produced in endothelial cells lining 
the vasculature, and secreted in response to endothelial cell 
activation or injury.9 It serves as an adhesion protein, recruiting 
circulating platelets to collect at that activation site and form 
a platelet plug. Just prior to platelet recruitment, vWF is 
present in circulation as a larger multimeric precursor protein, 
ultra-large vWF (UL-vWF), of which ADAMTS13 immediately 
cleaves into vWF for appropriate function in the clotting 
cascade. In the absence of ADAMTS13, UL-vWF released from 
vascular endothelial cells is not cleaved appropriately, which 
induces platelet hyperagglutination under high shear stress.9 
Uncleaved UL-vWF then binds to circulating platelets forming 
microthrombi, which both embolize into the microvasculature 
of end organs and cause fragmentation of adjacent circulating 
erythrocytes, thereby producing MAHA.
Epidemiology
The incidence and prevalence of USS is extremely rare. It 
is estimated that there have only been 100 cases worldwide 
to date, with an incidence rate of no more than 1/1,000,000 
person/year.9,10 USS comprises only 10% of all TTP patients with 
known ADAMTS13 deficiency,11 Time of initial presentation 
varies considerably; in one study of 43 USS patients in Japan, 
age of onset ranged from early childhood to 79 years.12,13 With 
regard to racial predilection, USS cases have been reported 
in all continents, although there is an increased reported 
incidence among patients of Japanese, Central European, and 
Jamaican descent.9 The most commonly reported mutation 
in ADAMTS13, c.4143dupA, was found through haplotype 
analyses to have a common ancestral background stemming 
from Central Europe.14 A single nucleotide polymorphism 
(SNP), specifically a p.P475S mutation, is reported to be 
relatively common among the Japanese population, with 9.6% 
of asymptomatic Japanese individuals being heterozygous for 
that single mutation.15
Clinical Course
The classical presentation of USS is an initial episode of severe 
neonatal jaundice with a negative Coombs test, requiring an 
exchange blood transfusion, and repeated childhood episodes 
of thrombocytopenia and MAHA, reversed by FFP, because of 
the repletion of the deficient ADAMTS13 metalloprotease.13 
However this is a rare occurrence and the majority of USS have 
a subclinical presentation, with significant variability in age of 
onset and severity of presentation.13 Patients may present young 
after typical childhood infections, during pregnancy, or even 
late in adulthood despite having prior stress triggers. Although 
patients who present early in life will likely have recurrent 
episodes of overt TTP, even adult presenters are subject to 
relapsing, recurrent disease.9 Presenting symptoms can range 
from singular asymptomatic episodes of thrombocytopenia to 
full-blown multi-organ failure and imminent death without 
treatment.3,9
Given that patients with USS can often have delayed onset of 
presentation and do not persistently manifest symptoms of overt 
TTP despite chronic deficiency in ADAMTS13, one questions 
the pathophysiology of the disease. Studies in ADAMTS13 gene 
knock-out mice revealed the presence of circulating UL-vWF 
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in the peripheral blood; however, these animal models did 
not manifest acute symptoms of overt TTP.16,17 Therefore, 
it is assumed that disease activity operates under a “two-hit 
hypothesis” in which the patient is chronically at increased 
risk for TTP, compared to patients with normal ADAMTS13 
activity, and can be considered as having a prothrombotic 
predisposition. Overt disease will not usually manifest unless 
instigated by a trigger or stress-inducing event, thereby 
representing the “second hit.”13 At the level of the microvascu-
lature, transient endothelial damage may occur, initiating the 
release of inflammatory cytokines and thrombomodulin, setting 
off a cascade heralding overt disease activity.18
Treatment
USS is initially treated in the same manner as ATTP, since 
the diagnosis of USS is usually obtained after the patient has 
already began treatment. Given the life-threatening and rapidly 
progressive course of untreated TTP, the standard of care, plasma 
exchange therapy, is immediately initiated upon the constellation 
of symptoms: thrombocytopenia, MAHA, and presence of 
schistocytes on peripheral smear. It is not appropriate to wait 
for determination of ADAMTS13 activity prior to beginning 
treatment. During plasma exchange, a venous-placed apheresis 
catheter removes blood from the patient, separates the blood 
cells from plasma, and returns the cells back while discarding the 
plasma in exchange for new donor plasma. This serves to remove 
the implicated autoantibody to ADAMTS13 in ATTP. However if 
it is determined that the patient has USS, he or she can be treated 
with FFP transfusions, which contain ADAMTS13, since the 
etiology of overt TTP in this case is due to a lack of ADAMTS13 
as opposed to inhibition of inherent ADAMTS13 activity.3 
Given the chronic, subclinical nature of USS, patients should 
receive expedited evaluation if they exhibit signs of infection, 
trauma, pregnancy, or alterations in their neurologic or renal 
function. Work-up should include a complete blood cell count 
with differential, haptoglobin, LDH, and peripheral blood smear 
to examine for schistocytes. Once determined that the USS 
patient is having an episode of overt TTP, he or she can receive 
FFP transfusions as well as erythrocyte and platelet transfusions 
until platelets reach 140 B/L and LDH has corrected to within 
normal range.
Additional developments in more curative forms of treatment 
for USS are currently under investigation. A recombinant human 
ADAMTS13 enzyme has been developed to correct deficiencies 
in vWF cleaving activity in vitro, as well as early studies in using 
monoclonal antibody rituximab for definitive therapy.19
Summary (a potential consideration in patients with progressive 
microangiopathic disease of brain, kidney unknown etiology)
USS, though very rare, is a chronic progressive disease that can 
easily become life-threatening without proper early recognition 
and treatment. Once diagnosed with USS, management should 
focus on preventative measures and early evaluation at the onset 
of disease triggers.3 Given the asymptomatic nature of the disease 
when the patient is in his or her normal state of health, it is safer 
and more cost-effective to treat with plasma transfusions and 
exchange therapy as needed only when symptoms arise, rather 
than scheduled sessions of transfusion treatment. However, this 
places the onus of responsibility on patients and their families. 
They must be educated on USS manifestations and motivated to 
pursue early evaluation as well as routine medical assessments 
for renal and neurologic abnormalities, which may signal an 
acutely developing disease.3
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